However, GnRH-agonist triggering is only ap-plicable in ovarian stimulation treatment regimen in which no desensitisation of the pituitary by a GnRH-agonist has been conducted. Because pi-tuitary desensitising GnRH-agonist protocols have become the most widely used standard in ovarian stimulation for IVF (Deutsches IVF Register, 1996-2006; FIVNAT 2004), GnRH-agonist usage for trig-gering final oocyte maturation in IVF patients has attained only little clinical interest until the market introdcution of the GnRH-antagonists.
GnRH-antagonists have emerged as an alterna-tive to GnRH-agonists in preventing premature LH surges (Diedrich et al., 1994; Olivennes et al., 1995). Due to the specific mode of action of the antagonist, the pituitary remains responsive to GnRH-agonist under GnRH-antagonist treatment in standard doses (Felberbaum et al., 1995). Several studies have demonstrated the feasibility of induc-ing an endogenous LH surge by administerinduc-ing a bolus dose of GnRH-agonist in a GnRH-antagonist protocol (Olivennes et al., 1996; Fauser et al., 2002, Beckers et al., 2003). As this manipulation has been suggested to prevent OHSS, its wider spread use
17-20 Nisan 2008, Çeşme - İZMİR
2005), recent research activities have focused on the following developments:
Modified luteal phase support
Data from a retrospective analysis (Engmann et al., 2006) and a RCT (Engmann et al., 2008) on OHSS risk patients indicate that GnRH-agonist and hCG are equivalent in terms of pregnancy like-lihood when intra-muscular progesterone (50 mg daily) combined with transdermal E2 (0.3 mg every other day) is used for luteal phase support, and when that regimen is continued in early pregnancy.
However, in the RCT the sample size is small, the study design is biased due to systematic differences in stimulation protocols and luteal phase support in the groups compared, while the external validity of this finding is unclear, as the overall pregnancy rate in both study arms is exceptionally high. In the trial of Fauser et al (2002), in which patients also received 50 mg intra-muscular progesterone, the outcome was comparable between hCG and agonist trigger. In contrast, a RCT of Babayof et al. (2006) on PCOS patients, in which i.m. progesterone and oral E2 were also used for LPS, finds live birth rate per embryo transfer not in favour of agonist trigger-ing (1/15 (6.7%) in agonist vs. 2/11 (18.2%) in hCG patients). In this trial early pregnancy loss occurred in 80% of pregnancies after agonist triggering as compared to 50 % after hCG. Therefore, the optimal dose, route, duration and combination of progester-one and E2 for luteal phase support after agonist triggering have not been sufficiently elucidated.
Another group (Humaidan et al., 2006; Humaid-an et al., 2007) has tested the concept of adding a low dose of hCG to the luteal phase after agonist triggering. 35h after a bolus of 0.5 mg buserelin, a single dose of 1500 IU hCG was shown to be able to restore normal corpus luteum function, and to secure a pregnancy likelihood comparable to that of hCG triggered final oocyte maturation in a RCT on 302 patients. The luteal phase was supplemented with vaginal progesterone (90mg/d) and oral E2 (4mg/d). However, this approach has to be scru-tinized because it involves hCG, and it is unclear whether or not an OHSS risk reduction can be achieved with this protocol - as the available trials have not been conducted specifically in OHSS risk populations.
Temporally or spatially splitting agonist triggering and embryo transfer
Addressing the issue of OHSS prevention with GnRH-agonist, the concept of temporal and spatial separation of agonist triggering and embryo trans-fer has also recently been explored.
In an ongoing observational study (Griesinger et al., 2007), forty patients considered at high OHSS risk (defined as ≥ 20 follicles ≥ 10 mm or E2 ≥ 4000 pg/ml or a history of cycle cancellation due to OHSS risk, or the development of severe OHSS in a previous cycle) after ovarian stimulation and concomitant GnRH-antagonist administration had final oocyte maturation triggered with 0.2 mg trip-torelin s.c. All 2 PN oocytes were cryopreserved by vitrification, and frozen-thawed embryo transfers were performed in subsequent artificial cycles with trans-dermal E2 and vaginal progesterone. The cumulative live birth rate was 32.5% (95% confi-dence interval: 21.7-45.5), while a 0% inciconfi-dence of moderate-to-severe OHSS was observed. The mean time to conception (oocyte pick-up to positive preg-nancy test leading to live birth) was 21 weeks and patients underwent a mean of 2.1 frozen-thawed embryo transfers. A further theoretical basis for splitting ovarian stimulation and embryo transfer temporally in OHSS risk patients is the possibility of the occurrence of a late-onset form of the disease in a pregnant woman due to revival of the multiple corpora lutea by early embryonic hCG. This is espe-cially relevant, as late-onset forms tend to be more often severe and of longer duration (Papanikolaou et al., 2006). Indeed, one of the rare cases of severe OHSS after agonist triggering reported in the liter-ature occurred as a late-onset OHSS in a pregnant woman (Chun et al., 2005).
The feasibility of GnRH-agonist triggering of final oocyte maturation in oocyte donation cycles has been tested in a RCT (Acevedo et al., 2006) and a large observational study (Bodri et al., 2007). It was shown that agonist triggering represents a safe treatment concept for the oocyte donor, while providing developmental competent oocytes for the recipient. Bodri et al. (2007) have found a 0% in-cidence of OHSS in 529 oocyte donation cycles, in which final oocyte maturation was triggered with triptorelin 0.2 mg (as opposed to 0.94% in donor cycles triggered with hCG). Likewise, Acevedo et al. (2006) described OHSS in 0/30 vs. 5/30 of oocyte donors that were ovulated with agonist and hCG, respectively. Outcome in the oocyte recipients was similar between agonist and hCG in both studies.
Conclusion
The use of GnRH agonist to trigger final oocyte maturation in IVF, where inhibition of premature LH surge is achieved with GnRH antagonists, yields a number of oocytes capable to undergo ferti-lization and subsequent embryonic cleavage, which is comparable to that achieved with hCG. However,
2. GÜNCEL ÜREME ENDOKRİNOLOJİSİ, YARDIMCI ÜREME TEKNİKLERİ KONGRESİ ve 1. ÜREME TIBBI DERNEĞİ KONGRESİ
it appears as if the luteolysis following agonist trig-gering also impairs pregnancy likelihood, and un-certainty persist about an optimal regimen of luteal phase support. For OHSS risk patients, the combi-nation of agonist triggering and cryopreservation of 2PN-oocytes/embryos is the most promising option to reduce the incidence of the syndrome, while pro-viding a good chance of pregnancy achievement for these patients, that otherwise face hospitalization due to OHSS, cycle cancellation or interventions of unknown efficacy, such as coasting. For oocyte donors, GnRH-agonist triggering appears to rep-resent a safe treatment concept, while providing developmental competent oocytes for the recipients.
Future research activities should aim at hCG (and therefore OHSS) free ovarian stimulation protocols that are safe, simple and efficacious, and that are easily applicable to all patients.
References
1. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006 Dec;86(6):1682-7
2. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006 May;21(5):1260-5
3. Balasch J, Tur R, Creus M, Buxaderas R, Fabregues F, Ballesca JL, Barri PN, Vanrell JA (1994) Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecol Endocrinol , 8(1):7-12
4. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC (2003) Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab, 88(9):4186-92
5. Bentick B, Shaw RW, Iffland CA, Burford G, Bernard A (1990) IVF pregnancy after induction of an ovulatory endogenous gonadotrophin surge using an LHRH agonist nasal spray. Hum Reprod, 5(5):570-2
6. Bodri D, Guillen JJ, Galindo A, Vidal R, Durban M, Coll O. Ovarian hyperstimulation syndrome in oocyte donors treated with a GnRH antagonist stimulation protocol. 14th World Congress of in vitro fertilization & 3rd World congress on in vitro maturation 2007. Montreal. Abstract book, 206.1 [oral]
7. Buckett WM, Bentick B, Shaw RW (1998) Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose. Hum Reprod, 13(4):811-4
8. Chun E (2005) Severe OHSS can be prevented in GnRH antagonist protocol using GnRH agonist to trigger ovulation. Fertil Steril 84 (Suppl 1), S301 (P-149).
9. Deutsches IVF Register (1996-2006). Annual reports from the German IVF registry 1996-2003 (http://www.deutsches-ivf-register.de)
10. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D (1994) Suppression of the endogenous LH-surge by the LH-RH antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9:788-791
11. Emperaire JC, Ruffie A (1991) Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod , 6(4):506-10
12. Engmann L, Siano L, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006 Nov;13(5):639-44
13. Engmann L, Diluigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2005) Prevention of Ovarian Hyperstimulation Syndrome (OHSS) with the use of Gonadotrophin Releasing Hormone (GnRH) agonist to trigger final oocyte maturation after co-treatment with GnRH antagonist in patients with polycystic ovarian syndrome (PCOS) or previous high response undergoing IVF treatment – a prospective randomised clinical trial. Fertil Steril.
2008 Jan;89(1):84-91
14. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG (2002) Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab, 87(2):709-15
15. Felberbaum RE, Reissmann T, Kupker W, Bauer O, al Hasani S, Diedrich C, Diedrich K (1995) Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol, 61(2):151-5
16. FIVNAT (2002) Annual report from the French IVF registry. Bilan provisoire 2002 (http://perso.
wanadoo.fr/fivnat.fr)
17. Gonen Y, Balakier H, Powell W, Casper RF (1990) Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab, 71(4):918-22
17-20 Nisan 2008, Çeşme - İZMİR
18. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006 Mar-Apr;12(2):159-68
19. Griesinger G, Kolibianakis EM, Papanikolaou EG, Diedrich K, Van Steirteghem A, Devroey P, Ejdrup Bredkjaer H, Humaidan P. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin.
Live birth after frozen-thawed embryo replacement cycles. Fertil Steril. 2007 Sep;88(3):616-21
20. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, Schultze-Mosgau A.
Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS:
a prospective, observational proof-of-concept study.
Hum Reprod. 2007 May;22(5):1348-52.
21. Humaidan P, Ejdrup Bredkjaer H, Bungum L, Bungum M, Grondahl ML, Westergaard L, Yding Andersen C (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Hum Reprod, 20(5):1213-1220.
22. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.
Reprod Biomed Online. 2006 Aug;13(2):173-8 23. Humaidan P, Ejdrup Bredkjaer, Westergaard L,
Yding Andersen C (2007) 1500 IU hCG secures a normal clinical pregnancy outcome in IVF/ICSI GnRH-antagonist cycles in which ovulation was triggered with a GnRH-agonist. Hum Reprod 22(Suppl.1): O-203 (i80)
24. Imoedemhe DA, Sigue AB, Pacpaco EL, Olazo AB (1991) Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril, 55(2):328-32 25. Itskovitz-Eldor, J, Kol, S and Mannaerts, B (2000)
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report:
short communication. Hum Reprod 15,1965-8 26. Kol S, Lewit N, Itskovitz-Eldor J (1996) Ovarian
hyperstimulation: effects of GnRH analogues.
Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Hum Reprod, 11(6):1143-4
27. Kol S, Itskovitz-Eldor J (2000) Severe OHSS: yes, there is a strategy to prevent it! Hum Reprod, 15(11):2266-7
28. Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum Reprod, 18(7):1557-8
29. Kol S (2004) Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril.
2004 Jan;81(1):1-5
30. Kolibianakis E, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, Griesinger G (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG, in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005 Oct;20(10):2887-92
31. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S (1994) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertil Steril, 62(1):35-41 32. Lewit N, Kol S, Manor D, Itskovitz-Eldor J (1996)
Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
Hum Reprod, 11(7):1399-402
33. Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R (1995) Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles:
a pilot study. Hum Reprod 10:1382-6
34. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R (1996) Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril, 66(1):151-3
35. Orvieto R (2005) Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod, 20(2):320-2
36. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P (2005b) Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile.
Hum Reprod,20,636-41.
37. Segal S and Casper RF (1992) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil Steril, 57(6):1254-8 38. Yding Andersen C, Humaidan P, Bredkjær Ejdrup
H, Bungum L, Grøndahl ML, and Westergaard LG.
Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum. Reprod., August 2006;
21: 2126 - 2130
using FSH together with agonists or antagonists.
The only group of patient which has to get LH is the hypogonadotropic hypogonadism. PCOS is another clinical entity where LH has to be exclu-ded of the therapy regime.
Mostly the LH suppression is profound at the late stages of follicular phase so if there is to be a benefit in adding LH to the induction protocole this should be done at this stage. A metaanalysis by Batista has shown that adding LH didnot re-sult in better pregnancy rates(30%/34%) although a significant difference was observed with a five fold high risk of early pregnancy loss (9%/45%) in the low LH group. On the contrary Kolibiniakis et al reported that low LH levels in normal or oligoanovulation patients in analogue cycles were not associated with higher miscarriage rates.
Serum LH levels measured at the time of Gn-RHantagonist administration and time of HCG injection have shown that a fall in LH levels less than 1/3 lead to a pregnancy rate of 18% where as the pregnancy rate was 39% in the control group (LH levels within 1/3). On the other hand Oli-vennes et al reported good pregnancy rates with high LH levels on the day of GnRH antagonist administration.
It is clear that LH is not only involved in folli-culogenesis but also in has effect on endometrial receptivity. Low LH levels can be responsible for implantation failures although when HCG is ad-ministered for the final maturation this negative effect maybe overcome.
It is clearly seen from the studies that have been done so far that there is no clear concensus on the issue about adding LH in ovulation induc-tion protocoles. GnRH analogue cycles and anta-gonist cycles respond differently where as every patient has a different response. Therefore there is stil need for randomized controlled studies and patient tailored protocoles.